MovDisordV3, Main, Exploration, bibRecord, 003B71

Quetiapine improves psychotic symptoms and cognition in Parkinson's disease

Identifieur interne : 003B71 ( Main/Exploration ); précédent : 003B70; suivant : 003B72

Quetiapine improves psychotic symptoms and cognition in Parkinson's disease

Auteurs : Jorge L. Juncos [États-Unis] ; Vicki J. Roberts [États-Unis] ; Marian L. Evatt [États-Unis] ; Rita D. Jewart [États-Unis] ; Colleen D. Wood [États-Unis] ; Larry S. Potter [États-Unis] ; Hann-Chang Jou [États-Unis] ; Paul P. Yeung [États-Unis]

Source :

Movement Disorders [ 0885-3185 ] ; 2004-01.

RBID : ISTEX:5FB7E5A4BB410D68D20BA0443FA25081A42E1336

Descripteurs français

Pascal (Inist)
- Cognition, Parkinson maladie, Quétiapine, Système nerveux pathologie.

English descriptors

KwdEn :
- Aged, Aged, 80 and over, Antiparkinson Agents (adverse effects), Antiparkinson Agents (therapeutic use), Antipsychotic Agents (adverse effects), Antipsychotic Agents (therapeutic use), Brief Psychiatric Rating Scale, Cognition, Delusions (chemically induced), Delusions (diagnosis), Delusions (drug therapy), Dibenzothiazepines (adverse effects), Dibenzothiazepines (therapeutic use), Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Follow-Up Studies, Hallucinations (chemically induced), Hallucinations (diagnosis), Hallucinations (drug therapy), Humans, Levodopa (adverse effects), Levodopa (therapeutic use), Male, Middle Aged, Nervous system diseases, Neurologic Examination (drug effects), Neuropsychological Tests, Parkinson Disease (drug therapy), Parkinson Disease (psychology), Parkinson disease, Parkinson's disease, Psychoses, Substance-Induced (diagnosis), Psychoses, Substance-Induced (drug therapy), Psychoses, Substance-Induced (psychology), Quetiapine, atypical antipsychotics, cognition, psychosis, quetiapine.
MESH :
- chemical , adverse effects : Antiparkinson Agents, Antipsychotic Agents, Dibenzothiazepines, Levodopa.
- chemical , therapeutic use : Antiparkinson Agents, Antipsychotic Agents, Dibenzothiazepines, Levodopa.
- chemically induced : Delusions, Hallucinations.
- diagnosis : Delusions, Hallucinations, Psychoses, Substance-Induced.
- drug effects : Neurologic Examination.
- drug therapy : Delusions, Hallucinations, Parkinson Disease, Psychoses, Substance-Induced.
- psychology : Parkinson Disease, Psychoses, Substance-Induced.
- Aged, Aged, 80 and over, Brief Psychiatric Rating Scale, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Follow-Up Studies, Humans, Male, Middle Aged, Neuropsychological Tests.

Abstract

Twenty‐nine elderly patients who failed treatment with clozapine, risperidone, or olanzapine entered this 24‐week, single‐center, open‐label trial to assess the efficacy of quetiapine (12.5–400 mg/day) for psychosis in patients with Parkinson's disease (PD). Psychiatric, motor, and cognitive assessments were administered at baseline and at periodic intervals for 24 weeks. These included the Brief Psychiatric Rating Scale (BPRS), Neuropsychiatric Inventory (NPI), Unified Parkinson's Disease Rating Scale (UPDRS) and tests of intellectual functioning, attention, and memory. Repeated measures statistical analysis was used to assess change from baseline. The results revealed significant improvements in the 24‐week BPRS total score and NPI psychosis subscale scores, with no decline in UPDRS total or motor subscale scores. There was also significant improvement in recall scores on cognitive measures. These results indicate that quetiapine may treat psychotic symptoms and improve cognition without worsening motor function in patients with PD, suggesting that quetiapine is an effective and well‐tolerated antipsychotic in this population. © 2003 Movement Disorder Society

Url:

https://api.istex.fr/document/5FB7E5A4BB410D68D20BA0443FA25081A42E1336/fulltext/pdf

DOI: 10.1002/mds.10620

Affiliations:

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Quetiapine improves psychotic symptoms and cognition in Parkinson's disease</title>
<author><name sortKey="Juncos, Jorge L" sort="Juncos, Jorge L" uniqKey="Juncos J" first="Jorge L." last="Juncos">Jorge L. Juncos</name>
</author>
<author><name sortKey="Roberts, Vicki J" sort="Roberts, Vicki J" uniqKey="Roberts V" first="Vicki J." last="Roberts">Vicki J. Roberts</name>
</author>
<author><name sortKey="Evatt, Marian L" sort="Evatt, Marian L" uniqKey="Evatt M" first="Marian L." last="Evatt">Marian L. Evatt</name>
</author>
<author><name sortKey="Jewart, Rita D" sort="Jewart, Rita D" uniqKey="Jewart R" first="Rita D." last="Jewart">Rita D. Jewart</name>
</author>
<author><name sortKey="Wood, Colleen D" sort="Wood, Colleen D" uniqKey="Wood C" first="Colleen D." last="Wood">Colleen D. Wood</name>
</author>
<author><name sortKey="Potter, Larry S" sort="Potter, Larry S" uniqKey="Potter L" first="Larry S." last="Potter">Larry S. Potter</name>
</author>
<author><name sortKey="Jou, Hann Hang" sort="Jou, Hann Hang" uniqKey="Jou H" first="Hann-Chang" last="Jou">Hann-Chang Jou</name>
</author>
<author><name sortKey="Yeung, Paul P" sort="Yeung, Paul P" uniqKey="Yeung P" first="Paul P." last="Yeung">Paul P. Yeung</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:5FB7E5A4BB410D68D20BA0443FA25081A42E1336</idno>
<date when="2004" year="2004">2004</date>
<idno type="doi">10.1002/mds.10620</idno>
<idno type="url">https://api.istex.fr/document/5FB7E5A4BB410D68D20BA0443FA25081A42E1336/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001822</idno>
<idno type="wicri:Area/Istex/Curation">001822</idno>
<idno type="wicri:Area/Istex/Checkpoint">002552</idno>
<idno type="wicri:doubleKey">0885-3185:2004:Juncos J:quetiapine:improves:psychotic</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:14743357</idno>
<idno type="wicri:Area/PubMed/Corpus">003580</idno>
<idno type="wicri:Area/PubMed/Curation">003580</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003341</idno>
<idno type="wicri:Area/Ncbi/Merge">000C84</idno>
<idno type="wicri:Area/Ncbi/Curation">000C84</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000C84</idno>
<idno type="wicri:doubleKey">0885-3185:2004:Juncos J:quetiapine:improves:psychotic</idno>
<idno type="wicri:Area/Main/Merge">005529</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:04-0233616</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002231</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000A90</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">002030</idno>
<idno type="wicri:doubleKey">0885-3185:2004:Juncos J:quetiapine:improves:psychotic</idno>
<idno type="wicri:Area/Main/Merge">005868</idno>
<idno type="wicri:Area/Main/Curation">003B71</idno>
<idno type="wicri:Area/Main/Exploration">003B71</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Quetiapine improves psychotic symptoms and cognition in Parkinson's disease</title>
<author><name sortKey="Juncos, Jorge L" sort="Juncos, Jorge L" uniqKey="Juncos J" first="Jorge L." last="Juncos">Jorge L. Juncos</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Neurology Department, Emory University, Atlanta, Georgia</wicri:regionArea>
<placeName><region type="state">Géorgie (États-Unis)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Roberts, Vicki J" sort="Roberts, Vicki J" uniqKey="Roberts V" first="Vicki J." last="Roberts">Vicki J. Roberts</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Neuropsychology Clinic, Atlanta, Georgia</wicri:regionArea>
<placeName><region type="state">Géorgie (États-Unis)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Evatt, Marian L" sort="Evatt, Marian L" uniqKey="Evatt M" first="Marian L." last="Evatt">Marian L. Evatt</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Neurology Department, Emory University, Atlanta, Georgia</wicri:regionArea>
<placeName><region type="state">Géorgie (États-Unis)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Jewart, Rita D" sort="Jewart, Rita D" uniqKey="Jewart R" first="Rita D." last="Jewart">Rita D. Jewart</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Psychiatry Department, Emory University, Atlanta, Georgia</wicri:regionArea>
<placeName><region type="state">Géorgie (États-Unis)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Wood, Colleen D" sort="Wood, Colleen D" uniqKey="Wood C" first="Colleen D." last="Wood">Colleen D. Wood</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Neurology Department, Emory University, Atlanta, Georgia</wicri:regionArea>
<placeName><region type="state">Géorgie (États-Unis)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Potter, Larry S" sort="Potter, Larry S" uniqKey="Potter L" first="Larry S." last="Potter">Larry S. Potter</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>AstraZeneca, Wilmington, Delaware</wicri:regionArea>
<placeName><region type="state">Delaware</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Jou, Hann Hang" sort="Jou, Hann Hang" uniqKey="Jou H" first="Hann-Chang" last="Jou">Hann-Chang Jou</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>AstraZeneca, Wilmington, Delaware</wicri:regionArea>
<placeName><region type="state">Delaware</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Yeung, Paul P" sort="Yeung, Paul P" uniqKey="Yeung P" first="Paul P." last="Yeung">Paul P. Yeung</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>AstraZeneca, Wilmington, Delaware</wicri:regionArea>
<placeName><region type="state">Delaware</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2004-01">2004-01</date>
<biblScope unit="vol">19</biblScope>
<biblScope unit="issue">1</biblScope>
<biblScope unit="page" from="29">29</biblScope>
<biblScope unit="page" to="35">35</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">5FB7E5A4BB410D68D20BA0443FA25081A42E1336</idno>
<idno type="DOI">10.1002/mds.10620</idno>
<idno type="ArticleID">MDS10620</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Aged, 80 and over</term>
<term>Antiparkinson Agents (adverse effects)</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Antipsychotic Agents (adverse effects)</term>
<term>Antipsychotic Agents (therapeutic use)</term>
<term>Brief Psychiatric Rating Scale</term>
<term>Cognition</term>
<term>Delusions (chemically induced)</term>
<term>Delusions (diagnosis)</term>
<term>Delusions (drug therapy)</term>
<term>Dibenzothiazepines (adverse effects)</term>
<term>Dibenzothiazepines (therapeutic use)</term>
<term>Dose-Response Relationship, Drug</term>
<term>Drug Administration Schedule</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Hallucinations (chemically induced)</term>
<term>Hallucinations (diagnosis)</term>
<term>Hallucinations (drug therapy)</term>
<term>Humans</term>
<term>Levodopa (adverse effects)</term>
<term>Levodopa (therapeutic use)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Nervous system diseases</term>
<term>Neurologic Examination (drug effects)</term>
<term>Neuropsychological Tests</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (psychology)</term>
<term>Parkinson disease</term>
<term>Parkinson's disease</term>
<term>Psychoses, Substance-Induced (diagnosis)</term>
<term>Psychoses, Substance-Induced (drug therapy)</term>
<term>Psychoses, Substance-Induced (psychology)</term>
<term>Quetiapine</term>
<term>atypical antipsychotics</term>
<term>cognition</term>
<term>psychosis</term>
<term>quetiapine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Antipsychotic Agents</term>
<term>Dibenzothiazepines</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Antipsychotic Agents</term>
<term>Dibenzothiazepines</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Delusions</term>
<term>Hallucinations</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Delusions</term>
<term>Hallucinations</term>
<term>Psychoses, Substance-Induced</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Neurologic Examination</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Delusions</term>
<term>Hallucinations</term>
<term>Parkinson Disease</term>
<term>Psychoses, Substance-Induced</term>
</keywords>
<keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Parkinson Disease</term>
<term>Psychoses, Substance-Induced</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Aged, 80 and over</term>
<term>Brief Psychiatric Rating Scale</term>
<term>Dose-Response Relationship, Drug</term>
<term>Drug Administration Schedule</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Neuropsychological Tests</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Cognition</term>
<term>Parkinson maladie</term>
<term>Quétiapine</term>
<term>Système nerveux pathologie</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Twenty‐nine elderly patients who failed treatment with clozapine, risperidone, or olanzapine entered this 24‐week, single‐center, open‐label trial to assess the efficacy of quetiapine (12.5–400 mg/day) for psychosis in patients with Parkinson's disease (PD). Psychiatric, motor, and cognitive assessments were administered at baseline and at periodic intervals for 24 weeks. These included the Brief Psychiatric Rating Scale (BPRS), Neuropsychiatric Inventory (NPI), Unified Parkinson's Disease Rating Scale (UPDRS) and tests of intellectual functioning, attention, and memory. Repeated measures statistical analysis was used to assess change from baseline. The results revealed significant improvements in the 24‐week BPRS total score and NPI psychosis subscale scores, with no decline in UPDRS total or motor subscale scores. There was also significant improvement in recall scores on cognitive measures. These results indicate that quetiapine may treat psychotic symptoms and improve cognition without worsening motor function in patients with PD, suggesting that quetiapine is an effective and well‐tolerated antipsychotic in this population. © 2003 Movement Disorder Society</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Delaware</li>
<li>Géorgie (États-Unis)</li>
</region>
</list>
<tree><country name="États-Unis"><region name="Géorgie (États-Unis)"><name sortKey="Juncos, Jorge L" sort="Juncos, Jorge L" uniqKey="Juncos J" first="Jorge L." last="Juncos">Jorge L. Juncos</name>
</region>
<name sortKey="Evatt, Marian L" sort="Evatt, Marian L" uniqKey="Evatt M" first="Marian L." last="Evatt">Marian L. Evatt</name>
<name sortKey="Jewart, Rita D" sort="Jewart, Rita D" uniqKey="Jewart R" first="Rita D." last="Jewart">Rita D. Jewart</name>
<name sortKey="Jou, Hann Hang" sort="Jou, Hann Hang" uniqKey="Jou H" first="Hann-Chang" last="Jou">Hann-Chang Jou</name>
<name sortKey="Potter, Larry S" sort="Potter, Larry S" uniqKey="Potter L" first="Larry S." last="Potter">Larry S. Potter</name>
<name sortKey="Roberts, Vicki J" sort="Roberts, Vicki J" uniqKey="Roberts V" first="Vicki J." last="Roberts">Vicki J. Roberts</name>
<name sortKey="Wood, Colleen D" sort="Wood, Colleen D" uniqKey="Wood C" first="Colleen D." last="Wood">Colleen D. Wood</name>
<name sortKey="Yeung, Paul P" sort="Yeung, Paul P" uniqKey="Yeung P" first="Paul P." last="Yeung">Paul P. Yeung</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003B71 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003B71 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:5FB7E5A4BB410D68D20BA0443FA25081A42E1336
   |texte=   Quetiapine improves psychotic symptoms and cognition in Parkinson's disease
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

Quetiapine improves psychotic symptoms and cognition in Parkinson's disease

Quetiapine improves psychotic symptoms and cognition in Parkinson's disease

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.